EMA Authorised: Januvia (sitagliptin) — Merck Sharp and Dohme B.V

View source ↗

Summary

EMA has authorized Januvia (sitagliptin) for type 2 diabetes mellitus. Merck Sharp & Dohme B.V. is the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Januvia (sitagliptin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Merck Sharp and Dohme B.V. Decision date: 30/10/2025